Published in J Immunol on July 01, 1999
Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. J Immunol (2004) 1.25
CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci U S A (2001) 1.22
The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One (2009) 1.07
Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron (2012) 1.05
Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol (2006) 0.96
T-cell clonotypes in cancer. J Transl Med (2004) 0.91
Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia. J Hematol Oncol (2010) 0.86
Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes. Oncoimmunology (2013) 0.81
Oligoclonal CD4+ T cells promote host memory immune responses to Zwitterionic polysaccharide of Streptococcus pneumoniae. Infect Immun (2009) 0.80
Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. JCI Insight (2016) 0.78
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res (1997) 2.98
Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. J Clin Oncol (1994) 2.14
Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest (1996) 2.10
Nonsense suppressors of Saccharomyces cerevisiae can be generated by mutation of the tyrosine tRNA anticodon. Nature (1976) 2.07
Biosynthesis of the beta and beta' subunits of RNA polymerase in Escherichia coli. J Mol Biol (1973) 2.03
Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer (1976) 1.97
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum (2006) 1.96
Replication of the F'lac sex factor in the cell cycle of Escherichia coli. Mol Gen Genet (1971) 1.92
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry (1982) 1.85
Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res (2001) 1.82
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene (2007) 1.72
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene (1999) 1.59
Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res (2001) 1.59
The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res (1996) 1.55
Hybridization of a myeloid leukemia-derived human cell line (K562) with a human Burkitt's lymphoma line (P3HR-1). J Natl Cancer Inst (1980) 1.53
A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer (1995) 1.52
In-tube DNA methylation profiling by fluorescence melting curve analysis. Clin Chem (2001) 1.51
Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J Cell Biol (1996) 1.50
Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines. Int J Cancer (1976) 1.41
Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood (1998) 1.41
Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. J Cancer Res Clin Oncol (2004) 1.39
Higher-order structure of human mitotic chromosomes. Proc Natl Acad Sci U S A (1977) 1.38
Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res (1997) 1.38
Anorectal melanoma: surgical management guidelines according to tumour thickness. Br J Cancer (2003) 1.37
Assignment of an autosomal sex reversal locus (SRA1) and campomelic dysplasia (CMPD1) to 17q24.3-q25.1. Nat Genet (1993) 1.33
Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia (2006) 1.31
Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J (1986) 1.31
Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood (1998) 1.27
Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity (2001) 1.26
Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol (1999) 1.24
Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol (2000) 1.24
Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res (1995) 1.24
Mutation analysis in glutaric aciduria type I. J Med Genet (2000) 1.23
Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. Eur J Haematol (2000) 1.22
Characterization of a human ovarian teratocarcinoma-derived cell line. Int J Cancer (1980) 1.19
Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol (1999) 1.19
High-performance liquid chromatography purification of homogenous-length RNA produced by trans cleavage with a hammerhead ribozyme. RNA (1999) 1.18
Simulation of the electrical and mechanical gradient of the small intestine. Am J Physiol (1968) 1.17
Multiple origins for phenylketonuria in Europe. Am J Hum Genet (1992) 1.17
Induction of carcinoma cell migration on vitronectin by NF-kappa B-dependent gene expression. Mol Biol Cell (1995) 1.16
Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. J Biol Chem (1985) 1.15
Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother (1998) 1.15
Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A (1996) 1.14
Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res (2000) 1.13
Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol (2000) 1.12
Merkel cell carcinoma--pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol (2011) 1.12
Molecular heterogeneity of classical and Duarte galactosemia: mutation analysis by denaturing gradient gel electrophoresis. Hum Mutat (1997) 1.11
Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat (1997) 1.09
Congenital heart disease in maternal phenylketonuria: report from the Maternal PKU Collaborative Study. Pediatr Res (2001) 1.09
Transformation induced by Epstein-Barr virus and the role of the nuclear antigen. Cold Spring Harb Symp Quant Biol (1980) 1.08
Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res (1999) 1.07
Asymptomatic carriage of toxigenic Clostridium difficile by hospitalized patients. J Hosp Infect (2013) 1.07
HLA antigen expression at the single cell level on a K562 X B cell hybrid: an analysis with monoclonal antibodies using bacterial binding assays. Somatic Cell Genet (1982) 1.06
Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J Biol Chem (2001) 1.05
Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med (1999) 1.05
An examination of coaxial stacking of helical stems in a pseudoknot motif: the gene 32 messenger RNA pseudoknot of bacteriophage T2. RNA (1999) 1.04
Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia (2013) 1.03
Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody. EMBO J (1984) 1.03
BDNF synthesis in spiral ganglion neurons is constitutive and CREB-dependent. Hear Res (2001) 1.02
Two-site time-resolved immunofluorometric assay of human insulin. Clin Chem (1986) 1.01
Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas. FEBS Lett (1998) 1.01
In situ T cells in melanoma. Cancer Immunol Immunother (1999) 1.01
BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report. Br J Dermatol (2012) 1.01
Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol (2000) 1.00
G(2) chromosomal radiosensitivity in Danish survivors of childhood and adolescent cancer and their offspring. Br J Cancer (2005) 1.00
TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol (2000) 1.00
Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens (2000) 1.00
Effect of smoking cessation on oxidative DNA modification estimated by 8-oxo-7,8-dihydro-2'-deoxyguanosine excretion. Carcinogenesis (1998) 1.00
Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification. EMBO J (1983) 0.99
Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res (1999) 0.98
Determination of exposure to aflatoxins among Danish workers in animal-feed production through the analysis of aflatoxin B1 adducts to serum albumin. Scand J Work Environ Health (1991) 0.98
Characterization of Sp1, AP-1, CBF and KRC binding sites and minisatellite DNA as functional elements of the metastasis-associated mts1/S100A4 gene intronic enhancer. Nucleic Acids Res (2001) 0.97
Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE). Biotechniques (1998) 0.97
Human salivary epidermal growth factor, haptocorrin and amylase before and after prolonged exercise. Scand J Clin Lab Invest (1988) 0.97
Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin C. Aliment Pharmacol Ther (2001) 0.97
Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme. Proc Natl Acad Sci U S A (1982) 0.97
Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother (2001) 0.96
Somatic cell hybrids between human lymphoma lines. III. Surface markers. Int J Cancer (1977) 0.96